blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2183249

EP2183249 - 8-Azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists [Right-click to bookmark this link]
Former [2010/19]8-AZABICYCLOÝ3.2.1 ỎCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
[2013/35]
StatusNo opposition filed within time limit
Status updated on  02.01.2015
Database last updated on 03.09.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Theravance Biopharma R&D IP, LLC
901 Gateway Boulevard
South San Francisco, CA 94080 / US
[2014/43]
Former [2010/19]For all designated states
Theravance, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080 / US
Inventor(s)01 / SAITO, Daisuke Roland
1515 Broadway Avenue Apt 1
Burlingame, California 94010 / US
02 / LONG, Daniel D.
4358 23rd Street
San Francisco, California 94114 / US
03 / VAN DYKE, Priscilla
550 Fell Street 5
San Francisco, California 94102 / US
04 / CHURCH, Timothy J.
3913 Pasadena Drive
San Mateo, California 94403 / US
05 / JIANG, Lan
788 Santa Maria Lane
Foster City, California 94404 / US
06 / FRIEMAN, Bryan
5220 Fiore Terrace
Apt 301
San Diego, California 92122 / US
 [2014/09]
Former [2010/19]01 / SAITO, Daisuke Roland
1515 Broadway Avenue Apt 1
Burlingame, California 94010 / US
02 / LONG, Daniel D.
4358 23rd Street
San Francisco, California 94114 / US
03 / VAN DYKE, Priscilla
550 Fell Street 5
San Francisco, California 94102 / US
04 / CHURCH, Timothy J.
3913 Pasadena Drive
San Mateo, California 94403 / US
05 / JIANG, Lan
788 Santa Maria Lane
Foster City, California 94404 / US
06 / FRIEMAN, Bryan
5220 Fiore Terrace Apt 301
San Diego, California 92122 / US
Representative(s)Scott, Susan Margaret, et al
Abel & Imray
20 Red Lion Street
London WC1R 4PQ / GB
[2014/09]
Former [2010/19]Scott, Susan Margaret, et al
Abel & Imray 20 Red Lion Street
London WC1R 4PQ / GB
Application number, filing date08795602.526.08.2008
[2010/19]
WO2008US10100
Priority number, dateUS20070966364P27.08.2007         Original published format: US 966364 P
US2008005106507.05.2008         Original published format: US 51065
[2010/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009029256
Date:05.03.2009
Language:EN
[2009/10]
Type: A1 Application with search report 
No.:EP2183249
Date:12.05.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 05.03.2009 takes the place of the publication of the European patent application.
[2010/19]
Type: B1 Patent specification 
No.:EP2183249
Date:26.02.2014
Language:EN
[2014/09]
Search report(s)International search report - published on:EP05.03.2009
ClassificationIPC:C07D451/02, A61K31/46, A61P1/04, A61P1/08
[2010/19]
CPC:
C07D471/08 (EP,US); A61K31/46 (EP,US); A61K31/485 (EP,US);
A61P1/00 (EP); A61P1/04 (EP); A61P1/06 (EP);
A61P1/08 (EP); A61P1/10 (EP); A61P25/04 (EP);
A61P43/00 (EP); C07D451/02 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/19]
TitleGerman:8-Azabicyclo[3.2.1]octyl-2-hydroxybenzamid-Verbindungen zur Verwendung als mü-Opioidrezeptor-Antagonisten[2013/35]
English:8-Azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists[2013/35]
French:Composés de 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide utilisés en tant qu'antagonistes du récepteur opioide mu[2013/35]
Former [2010/19]8-AZABICYCLO[3.2.1]OKTYL-2-HYDROXYBENZAMID-VERBINDUNGEN ALS MU-OPIOID-REZEPTORANTAGONISTEN
Former [2010/19]8-AZABICYCLOÝ3.2.1 ỎCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
Former [2010/19]COMPOSES DE 8-AZABICYCLOÝ3.2.1 ỎCTYL-2-HYDROXYBENZAMIDE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR OPIOIDE MU
Entry into regional phase18.02.2010National basic fee paid 
18.02.2010Designation fee(s) paid 
18.02.2010Examination fee paid 
Examination procedure18.02.2010Amendment by applicant (claims and/or description)
18.02.2010Examination requested  [2010/19]
25.02.2013Despatch of a communication from the examining division (Time limit: M04)
17.06.2013Reply to a communication from the examining division
03.09.2013Communication of intention to grant the patent
10.01.2014Fee for grant paid
10.01.2014Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.02.2013
Opposition(s)27.11.2014No opposition filed within time limit [2015/06]
Fees paidRenewal fee
25.08.2010Renewal fee patent year 03
25.08.2011Renewal fee patent year 04
27.08.2012Renewal fee patent year 05
27.08.2013Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.08.2008
AT26.02.2014
BG26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
MT26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SI26.02.2014
SK26.02.2014
TR26.02.2014
NO26.05.2014
GR27.05.2014
IS26.06.2014
PT26.06.2014
LU26.08.2014
[2016/33]
Former [2016/32]HU26.08.2008
AT26.02.2014
BG26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
MT26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SI26.02.2014
SK26.02.2014
NO26.05.2014
GR27.05.2014
IS26.06.2014
PT26.06.2014
LU26.08.2014
Former [2016/28]AT26.02.2014
BG26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
MT26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SI26.02.2014
SK26.02.2014
NO26.05.2014
GR27.05.2014
IS26.06.2014
PT26.06.2014
LU26.08.2014
Former [2016/25]AT26.02.2014
BG26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SI26.02.2014
SK26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
LU26.08.2014
Former [2015/24]AT26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SI26.02.2014
SK26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
LU26.08.2014
Former [2015/19]AT26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SK26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
LU26.08.2014
Former [2015/18]AT26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
MC26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SK26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/50]AT26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
NL26.02.2014
PL26.02.2014
RO26.02.2014
SE26.02.2014
SK26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/49]AT26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
NL26.02.2014
RO26.02.2014
SE26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/48]AT26.02.2014
CY26.02.2014
CZ26.02.2014
DK26.02.2014
EE26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
NL26.02.2014
SE26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/41]AT26.02.2014
CY26.02.2014
FI26.02.2014
HR26.02.2014
LT26.02.2014
LV26.02.2014
NL26.02.2014
SE26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/39]AT26.02.2014
CY26.02.2014
FI26.02.2014
LT26.02.2014
NL26.02.2014
SE26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/37]AT26.02.2014
CY26.02.2014
FI26.02.2014
LT26.02.2014
SE26.02.2014
NO26.05.2014
IS26.06.2014
PT26.06.2014
Former [2014/36]LT26.02.2014
NO26.05.2014
IS26.06.2014
Cited inInternational search[A]WO2004089908  (PFIZER PROD INC [US], et al) [A] 1,14-20 * example -; claims 1-3,10-12 *;
 [A]WO2004089909  (PFIZER PROD INC [US], et al) [A] 1,14-20 * example -; claims 1,16,17 *;
 [AP]WO2007103187  (THERAVANCE INC [US], et al) [AP] 1,2,5,8,9,11,13-21 * claims 1,8,15-26 *
 [A]  - ZHIJAN LU ET AL, "Substituted Bridged Phenyl Piperidines: Orally Active Growth Hormone Secretagogues", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, (20030101), vol. 13, ISSN 0960-894X, pages 1817 - 1820, XP002449068 [A] 1 * page 1819, scheme 4; table 1 *

DOI:   http://dx.doi.org/10.1016/S0960-894X(03)00261-0
by applicantWO2004089908
 WO2004089909
 WO2007103187
    - BIOORG. AND MED. CHEM. LETT., (2003), vol. 13, pages 1817 - 1820
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.